BRAF V600E mutation is associated with mTOR signaling activation in glioneuronal tumors

Brain Pathology

Volumn 24, Issue 1, 2014, Pages 52-66

  Prabowo, Avanita S ^a   Iyer, Anand M ^a   Veersema, Tim J ^b   Anink, Jasper J ^a   Schouten Van Meeteren, Antoinette Y N ^a   Spliet, Wim G M ^b   Van Rijen, Pieter C ^b   Ferrier, Cyrille H ^b,c   Capper, David ^d,e   Thom, Maria ^f   Aronica, Eleonora ^a,g,h  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^h UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

BRAF; immunohistochemistry; inflammation; long term epilepsy associated tumors; mTOR; sequencing

Indexed keywords

B RAF KINASE; CD34 ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN S6; S6 KINASE; SYNAPTOPHYSIN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTE; BRAIN TUMOR; CELL POPULATION; CHILD; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE DURATION; DNA SEQUENCE; DYSEMBRYOPLASTIC INFANTILE TUMOR; FEMALE; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INFANT; MAJOR CLINICAL STUDY; MALE; MICROGLIA; MOLECULAR GENETICS; MUTATION; NEUROEPITHELIOMA; PRESCHOOL CHILD; PROTEIN EXPRESSION; SCHOOL CHILD;

BRAF; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LONG-TERM EPILEPSY ASSOCIATED TUMORS; MTOR; SEQUENCING;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RIBOSOMAL PROTEIN S6; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84890804300     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/bpa.12081     Document Type: Article

References (68)

1. Alayev A, Holz MK, (2013) mTOR signaling for biological control and cancer. J Cell Physiol 228: 1658-1664.
2. Andersen MH, Fensterle J, Ugurel S, Reker S, Houben R, Guldberg P, et al (2004) Immunogenicity of constitutively active V599EBRaf. Cancer Res 64: 5456-5460.
3. Anjum R, Blenis J, (2008) The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol 9: 747-758.
4. Aronica E, Gorter JA, Jansen GH, van Veelen CW, van Rijen PC, Ramkema M, Troost D, (2003) Expression and cell distribution of group I and group II metabotropic glutamate receptor subtypes in taylor-type focal cortical dysplasia. Epilepsia 44: 785-795. (Pubitemid 36754003)
5. Aronica E, Gorter JA, Redeker S, Ramkema M, Spliet WG, van Rijen PC, et al (2005) Distribution, characterization and clinical significance of microglia in glioneuronal tumours from patients with chronic intractable epilepsy. Neuropathol Appl Neurobiol 31: 280-291. (Pubitemid 40769527)
6. Aronica E, Boer K, Baybis M, Yu J, Crino PB, (2007) Co-expression of cyclin D1 and phosphorylated ribosomal S6 proteins in hemimegalencephaly. Acta Neuropathol 114: 287-293. (Pubitemid 47226155)
7. Aronica E, Ravizza T, Zurolo E, Vezzani A, (2012) Astrocyte immune responses in epilepsy. Glia 60: 1258-1268.
8. Astrinidis A, Henske EP, (2005) Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene 24: 7475-7481. (Pubitemid 41637987)
9. Barkovich AJ, Guerrini R, Kuzniecky RI, Jackson GD, Dobyns WB, (2012) A developmental and genetic classification for malformations of cortical development: update 2012. Brain 135 (Pt 5): 1348-1369.
10. Becker AJ, Lobach M, Klein H, Normann S, Nothen MM, von Deimling A, et al (2001) Mutational analysis of TSC1 and TSC2 genes in gangliogliomas. Neuropathol Appl Neurobiol 27: 105-114. (Pubitemid 32591967)
11. Becker AJ, Blumcke I, Urbach H, Hans V, Majores M, (2006) Molecular neuropathology of epilepsy-associated glioneuronal malformations. J Neuropathol Exp Neurol 65: 99-108.
12. Blumcke I, Wiestler OD, (2002) Gangliogliomas: an intriguing tumor entity associated with focal epilepsies. J Neuropathol Exp Neurol 61: 575-584. (Pubitemid 34727339)
13. Blumcke I, Giencke K, Wardelmann E, Beyenburg S, Kral T, Sarioglu N, et al (1999) The CD34 epitope is expressed in neoplastic and malformative lesions associated with chronic, focal epilepsies. Acta Neuropathol 97: 481-490. (Pubitemid 29195111)
14. Blümcke I, Vinters HV, Armstrong D, Aronica E, Thom M, Spreafico R, (2009) Malformations of cortical development and epilepsies: neuropathological findings with emphasis on focal cortical dysplasia. Epileptic Disord 11: 181-193.
15. Blumcke I, Thom M, Aronica E, Armstrong DD, Vinters HV, Palmini A, et al (2011) The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia 52: 158-174.
16. Blumcke I, Thom M, Aronica E, Armstrong DD, Bartolomei F, Bernasconi A, et al (2013) International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: a task force report from the ILAE Commission on Diagnostic Methods. Epilepsia 54: 1315-1329.
17. Bodi I, Selway R, Bannister P, Doey L, Mullatti N, Elwes R, Honavar M, (2012) Diffuse form of dysembryoplastic neuroepithelial tumour: the histological and immunohistochemical features of a distinct entity showing transition to dysembryoplastic neuroepithelial tumour and ganglioglioma. Neuropathol Appl Neurobiol 38: 411-425.
18. Boer K, Troost D, Timmerman W, Spliet WGM, van Rijen PC, Aronica E, (2010) Pi3K-mTOR signaling and AMOG expression in epilepsy-associated glioneuronal tumors. Brain Pathol 20: 234-244.
19. Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, et al (2011) Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 122: 11-19.
20. Chappe C, Padovani L, Scavarda D, Forest F, Nanni-Metellus I, Loundou A, et al (2013) Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF mutation and expression. Brain Pathol 23: 574-583.
21. Crino PB, (2011) mTOR: a pathogenic signaling pathway in developmental brain malformations. Trends Mol Med 17: 734-742.
22. Dahiya S, Haydon DH, Alvarado D, Gurnett CA, Gutmann DH, Leonard JR, (2013) BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathol 125: 901-910.
23. Dazert E, Hall MN, (2011) mTOR signaling in disease. Curr Opin Cell Biol 23: 744-755.
24. De Tommasi A, Luzzi S, D'Urso PI, De Tommasi C, Resta N, Ciappetta P, (2008) Molecular genetic analysis in a case of ganglioglioma: identification of a new mutation. Neurosurgery 63: 976-980; discussion 80.
25. Deb P, Sharma MC, Tripathi M, Sarat Chandra P, Gupta A, Sarkar C, (2006) Expression of CD34 as a novel marker for glioneuronal lesions associated with chronic intractable epilepsy. Neuropathol Appl Neurobiol 32: 461-468. (Pubitemid 44401508)
26. Dougherty MJ, Santi M, Brose MS, Ma C, Resnick AC, Sievert AJ, et al (2010) Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol 12: 621-630.
27. Edlundh-Rose E, Egyhazi S, Omholt K, Mansson-Brahme E, Platz A, Hansson J, Lundeberg J, (2006) NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 16: 471-478. (Pubitemid 44934704)
28. Eisenhardt AE, Olbrich H, Roring M, Janzarik W, Anh TN, Cin H, et al (2011) Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma. Int J Cancer 129: 2297-2303.
29. Engel JJ, (1993) Outcome with respect to epileptic seizures. In: Surgical Treatment of the Epilepsies, JJ Engel, (ed.), pp. 609-621. Raven Press: New York.
30. Esteve-Puig R, Canals F, Colome N, Merlino G, Recio JA, (2009) Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF. Plos One 4: e4771.
31. Fauser S, Becker A, Schulze-Bonhage A, Hildebrandt M, Tuxhorn I, Pannek HW, et al (2004) CD34-immunoreactive balloon cells in cortical malformations. Acta Neuropathol 108: 272-278. (Pubitemid 39317694)
32. Faustino A, Couto JP, Populo H, Rocha AS, Pardal F, Cameselle-Teijeiro JM, et al (2012) mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. J Clin Endocrinol Metab 97: E1139-E1149.
33. Fensterle J, Becker JC, Potapenko T, Heimbach V, Vetter CS, Brocker EB, Rapp UR, (2004) B-Raf specific antibody responses in melanoma patients. BMC Cancer 4: 62.
34. Galanopoulou AS, Gorter JA, Cepeda C, (2012) Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target. Epilepsia 53: 1119-1130.
35. Han S, Santos TM, Puga A, Roy J, Thiele EA, McCollin M, et al (2004) Phosphorylation of tuberin as a novel mechanism for somatic inactivation of the tuberous sclerosis complex proteins in brain lesions. Cancer Res 64: 812-816. (Pubitemid 38176876)
36. Horbinski C, (2013) To BRAF or not to BRAF: is that even a question anymore? J Neuropathol Exp Neurol 72: 2-7.
37. Iyer A, Zurolo E, Spliet WG, van Rijen PC, Baayen JC, Gorter JA, Aronica E, (2010) Evaluation of the innate and adaptive immunity in type I and type II focal cortical dysplasias. Epilepsia 51: 1763-1773.
38. Jozwiak J, Wlodarski P, (2006) Hamartin and tuberin modulate gene transcription via beta-catenin. J Neurooncol 79: 229-234. (Pubitemid 44363725)
39. Kam R, Chen J, Blumcke I, Normann S, Fassunke J, Elger CE, et al (2004) The reelin pathway components disabled-1 and p35 in gangliogliomas-a mutation and expression analysis. Neuropathol Appl Neurobiol 30: 225-232. (Pubitemid 38789244)
40. Koelsche C, Sahm F, Paulus W, Mittelbronn M, Giangaspero F, Antonelli M, et al (2013) BRAF V600E expression and distribution in desmoplastic infantile astrocytoma/ganglioglioma. Neuropathol Appl Neurobiol. doi: 10.1111/nan.12072.
41. Koelsche C, Wohrer A, Jeibmann A, Schittenhelm J, Schindler G, Preusser M, et al (2013) Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol 125: 891-900.
42. Korshunov A, Ryzhova M, Jones DT, Northcott PA, van Sluis P, Volckmann R, et al (2012) LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). Acta Neuropathol 124: 875-881.
43. Kwiatkowski DJ, Manning BD, (2005) Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet 14 (Spec No. 2): R251-R258. (Pubitemid 41631882)
44. Li WQ, Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Iacopetta B, (2006) BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer 5: 2-7.
45. Lim HK, Choi YA, Park W, Lee T, Ryu SH, Kim SY, et al (2003) Phosphatidic acid regulates systemic inflammatory responses by modulating the Akt-mammalian target of rapamycin-p70 S6 kinase 1 pathway. J Biol Chem 278: 45117-45127. (Pubitemid 37432644)
46. Louis DN, Ohgaki H, Wiestler OD, Cavanee WK, (2007) WHO Classification of Tumours of the Central Nervous System. IARC: Lyon.
47. Mak BC, Kenerson HL, Aicher LD, Barnes EA, Yeung RS, (2005) Aberrant beta-catenin signaling in tuberous sclerosis. Am J Pathol 167: 107-116. (Pubitemid 40894642)
48. McDaniel SS, Wong M, (2011) Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis. Neurosci Lett 497: 231-239.
49. Orlova KA, Tsai V, Baybis M, Heuer GG, Sisodiya S, Thom M, et al (2010) Early progenitor cell marker expression distinguishes type II from type I focal cortical dysplasias. J Neuropathol Exp Neurol 69: 850-863.
50. Parry L, Maynard JH, Patel A, Hodges AK, von Deimling A, Sampson JR, Cheadle JP, (2000) Molecular analysis of the TSC1 and TSC2 tumour suppressor genes in sporadic glial and glioneuronal tumours. Hum Genet 107: 350-356.
51. Prabowo AS, Iyer AM, Anink JJ, Spliet WG, van Rijen PC, Aronica E, (2013) Differential expression of major histocompatibility complex class I in developmental glioneuronal lesions. J Neuroinflammation 10: 12.
52. Ravizza T, Boer K, Redeker S, Spliet WG, van Rijen PC, Troost D, et al (2006) The IL-1beta system in epilepsy-associated malformations of cortical development. Neurobiol Dis 24: 128-143. (Pubitemid 44416213)
53. Resta N, Lauriola L, Puca A, Susca FC, Albanese A, Sabatino G, et al (2006) Ganglioglioma arising in a Peutz-Jeghers patient: a case report with molecular implications. Acta Neuropathol 112: 106-111. (Pubitemid 43942167)
54. Rosner M, Hanneder M, Siegel N, Valli A, Fuchs C, Hengstschlager M, (2008) The mTOR pathway and its role in human genetic diseases. Mutat Res 659: 284-292.
55. Schick V, Majores M, Engels G, Hartmann W, Elger CE, Schramm J, et al (2007) Differential Pi3K-pathway activation in cortical tubers and focal cortical dysplasias with balloon cells. Brain Pathol 17: 165-173. (Pubitemid 46466136)
56. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, et al (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121: 397-405.
57. Schmitz F, Heit A, Dreher S, Eisenacher K, Mages J, Haas T, et al (2008) Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells. Eur J Immunol 38: 2981-2992.
58. Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA, Cantley LC, (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6: 91-99. (Pubitemid 38903165)
59. Thom M, Toma A, An S, Martinian L, Hadjivassiliou G, Ratilal B, et al (2011) One hundred and one dysembryoplastic neuroepithelial tumors: an adult epilepsy series with immunohistochemical, molecular genetic, and clinical correlations and a review of the literature. J Neuropathol Exp Neurol 70: 859-878.
60. Thom M, Blumcke I, Aronica E, (2012) Long-term epilepsy-associated tumors. Brain Pathol 22: 350-379.
61. Trinh XB, Tjalma WA, Vermeulen PB, Van den Eynden G, Van der Auwera I, Van Laere SJ, et al (2009) The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer 100: 971-978.
62. van Veelen CW, Debets RM, van Huffelen AC, de Boas W, Binnie CD, Storm van Leeuwen W, et al (1990) Combined use of subdural and intracerebral electrodes in preoperative evaluation of epilepsy. Neurosurgery 26: 93-101. (Pubitemid 20209545)
63. Vezzani A, (2012) Before epilepsy unfolds: finding the epileptogenesis switch. Nat Med 18: 1626-1627.
64. Vezzani A, French J, Bartfai T, Baram TZ, (2011) The role of inflammation in epilepsy. Nat Rev Neurol 7: 31-40.
65. Vezzani A, Auvin S, Ravizza T, Aronica E, (2012) Glia-neuronal interactions in ictogenesis and epileptogenesis: role of inflammatory mediators. In: Jasper's Basic Mechanisms of the Epilepsies, 4th edn., JL Noebels, M Avoli, MA Rogawski, RW Olsen, AV Delgado-Escueta, (eds), pp. 1-21. National Center for Biotechnology Information (USA): Bethesda, MD.
66. Weichhart T, Saemann MD, (2009) The multiple facets of mTOR in immunity. Trends Immunol 30: 218-226.
67. Zemke D, Azhar S, Majid A, (2007) The mTOR pathway as a potential target for the development of therapies against neurological disease. Drug News Perspect 20: 495-499. (Pubitemid 351182792)
68. Zheng B, Jeong JH, Asara JM, Yuan YY, Granter SR, Chin L, Cantley LC, (2009) Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 33: 237-247.